Dacarbazine


Dacarbazine (DTIC) is an imidazole carboxamide used in the treatment of malignant melanoma, sarcomas, Hodgkin’s disease and neuroblastoma.
 
Incidence
Anaphylactic shock: one case.
 
More common for photosensitivity and hepatitis.
 
Clinical manifestations
General: anaphylactic shock (one case).
 
Cutaneous: photosensitivity, localized skin reaction, pruritus, erythema, edema.
 
Hepatic: allergic hepatitis (allergic hepatic veno-occlusive disorder: Budd-Chiari syndrome).
 
Diagnostic methods
None.
 
Mechanisms
Unknown.
 
Management
Avoidance.

References

  1. Serrano G, Aliaga A, Febrer I, "Dacarbazine induced photosensitivity", Photodermatology, 1989; 6: 140-1
  2. Abhyankar S, Rao S.P, Pollio L, Miller S.T, "Anaphylactic shock due to dacarbazine", Am. J. Dis. Child., 1988; 142 (9): 918
  3. Mc Clay E, Lusch C.J, Mastrangelo M.J, "Allergy-induced hepatic toxicity associated with dacarbazine", Cancer Treat. Rep, 1987; 71 (2): 219-20
  4. Koehn G.G, Balizet L.B, "Unusual local cutaneous reaction to dacarbazine", Arch. Dermatol., 1982; 118 (12): 1018-9

As in all diagnostic testing, the diagnosis is made by the physican based on both test results and the patient history.